Roi Weiser1, Waqar Haque2, Efstathia Polychronopoulou3, Sandra S Hatch4, Yong-Fang Kuo3, William J Gradishar5, V Suzanne Klimberg6. 1. Department of Surgery, University of Texas Medical Branch, 301 University Blvd., Galveston, TX, 77555-0737, USA. roweiser@utmb.edu. 2. Department of Radiation Oncology, Houston Methodist Hospital, Houston, TX, USA. 3. Office of Biostatistics, Department of Preventive Medicine and Population Health, University of Texas Medical Branch, Galveston, TX, USA. 4. Department of Radiation Oncology, University of Texas Medical Branch, Galveston, TX, USA. 5. Department of Medicine & Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA. 6. Department of Surgery, University of Texas Medical Branch, 301 University Blvd., Galveston, TX, 77555-0737, USA. vsklimbe@utmb.edu.
Abstract
PURPOSE: The 21-gene recurrence score assay (RS) has not been prospectively validated to predict adjuvant chemotherapy benefit in hormone receptor-positive (HR+), HER2-negative (HER2-), node-positive breast cancer patients. Nevertheless, de-escalation based on RS has been demonstrated and partially advocated by retrospective data. The purpose of this study was to identify subgroups of node-positive patients with low to intermediate RS who still benefit from adjuvant chemotherapy. METHODS: The National Cancer Database was used to identify 28,591 women with stage I-III, T1-T3, N1, HR+, HER2- breast cancer and a RS ≤ 25 between 2010 and 2016. Univariate and multivariate analyses were used to identify variables correlating with chemotherapy use and 5-year survival. Subgroup analysis was performed to discern patients in whom the use of adjuvant chemotherapy correlated with better survival. RESULTS: A 35% decline in chemotherapy use was observed from 2010 to 2016. Patients with younger age, higher RS, larger tumors and more positive lymph nodes, and those treated by mastectomy, axillary lymph node dissection and radiation, were more likely to receive chemotherapy. Chemotherapy use was associated with an improved 5-year survival (HR = 1.63, 95% CI 1.28-2.07). Upon subgroup analysis, this association was lost in patients > 70 years and those with a RS ≤ 11, while patients ≤ 70 with a RS of 12-25 treated with chemotherapy had an absolute 5-year survival advantage of 3.0% (HR = 1.91, 95% CI 1.42-2.57). CONCLUSION: Clinicians should be cautious when considering omission of adjuvant chemotherapy in patients ≤ 70 years, with HR+, HER2-, N1 tumors and a RS 12-25, at least until the results of the anticipated RxPONDER trial become available.
PURPOSE: The 21-gene recurrence score assay (RS) has not been prospectively validated to predict adjuvant chemotherapy benefit in hormone receptor-positive (HR+), HER2-negative (HER2-), node-positive breast cancerpatients. Nevertheless, de-escalation based on RS has been demonstrated and partially advocated by retrospective data. The purpose of this study was to identify subgroups of node-positive patients with low to intermediate RS who still benefit from adjuvant chemotherapy. METHODS: The National Cancer Database was used to identify 28,591 women with stage I-III, T1-T3, N1, HR+, HER2- breast cancer and a RS ≤ 25 between 2010 and 2016. Univariate and multivariate analyses were used to identify variables correlating with chemotherapy use and 5-year survival. Subgroup analysis was performed to discern patients in whom the use of adjuvant chemotherapy correlated with better survival. RESULTS: A 35% decline in chemotherapy use was observed from 2010 to 2016. Patients with younger age, higher RS, larger tumors and more positive lymph nodes, and those treated by mastectomy, axillary lymph node dissection and radiation, were more likely to receive chemotherapy. Chemotherapy use was associated with an improved 5-year survival (HR = 1.63, 95% CI 1.28-2.07). Upon subgroup analysis, this association was lost in patients > 70 years and those with a RS ≤ 11, while patients ≤ 70 with a RS of 12-25 treated with chemotherapy had an absolute 5-year survival advantage of 3.0% (HR = 1.91, 95% CI 1.42-2.57). CONCLUSION: Clinicians should be cautious when considering omission of adjuvant chemotherapy in patients ≤ 70 years, with HR+, HER2-, N1tumors and a RS 12-25, at least until the results of the anticipated RxPONDER trial become available.
Authors: Soonmyung Paik; Steven Shak; Gong Tang; Chungyeul Kim; Joffre Baker; Maureen Cronin; Frederick L Baehner; Michael G Walker; Drew Watson; Taesung Park; William Hiller; Edwin R Fisher; D Lawrence Wickerham; John Bryant; Norman Wolmark Journal: N Engl J Med Date: 2004-12-10 Impact factor: 91.245
Authors: Nadia Howlader; Sean F Altekruse; Christopher I Li; Vivien W Chen; Christina A Clarke; Lynn A G Ries; Kathleen A Cronin Journal: J Natl Cancer Inst Date: 2014-04-28 Impact factor: 13.506
Authors: Kathy S Albain; William E Barlow; Steven Shak; Gabriel N Hortobagyi; Robert B Livingston; I-Tien Yeh; Peter Ravdin; Roberto Bugarini; Frederick L Baehner; Nancy E Davidson; George W Sledge; Eric P Winer; Clifford Hudis; James N Ingle; Edith A Perez; Kathleen I Pritchard; Lois Shepherd; Julie R Gralow; Carl Yoshizawa; D Craig Allred; C Kent Osborne; Daniel F Hayes Journal: Lancet Oncol Date: 2009-12-10 Impact factor: 41.316
Authors: Joseph A Sparano; Robert J Gray; Della F Makower; Kathleen I Pritchard; Kathy S Albain; Daniel F Hayes; Charles E Geyer; Elizabeth C Dees; Matthew P Goetz; John A Olson; Tracy Lively; Sunil S Badve; Thomas J Saphner; Lynne I Wagner; Timothy J Whelan; Matthew J Ellis; Soonmyung Paik; William C Wood; Peter M Ravdin; Maccon M Keane; Henry L Gomez Moreno; Pavan S Reddy; Timothy F Goggins; Ingrid A Mayer; Adam M Brufsky; Deborah L Toppmeyer; Virginia G Kaklamani; Jeffrey L Berenberg; Jeffrey Abrams; George W Sledge Journal: N Engl J Med Date: 2018-06-03 Impact factor: 91.245
Authors: Salomon M Stemmer; Shmuel H Klang; Noa Ben-Baruch; David B Geffen; Mariana Steiner; Lior Soussan-Gutman; Shahar Merling; Christer Svedman; Shulamith Rizel; Nicky Lieberman Journal: Breast Cancer Res Treat Date: 2013-06-26 Impact factor: 4.872
Authors: Ulrike Nitz; Oleg Gluz; Matthias Christgen; Ronald E Kates; Michael Clemens; Wolfram Malter; Benno Nuding; Bahriye Aktas; Sherko Kuemmel; Toralf Reimer; Andrea Stefek; Fatemeh Lorenz-Salehi; Petra Krabisch; Marianne Just; Doris Augustin; Cornelia Liedtke; Calvin Chao; Steven Shak; Rachel Wuerstlein; Hans H Kreipe; Nadia Harbeck Journal: Breast Cancer Res Treat Date: 2017-06-29 Impact factor: 4.872
Authors: Kevin Kalinsky; William E Barlow; Julie R Gralow; Funda Meric-Bernstam; Kathy S Albain; Daniel F Hayes; Nancy U Lin; Edith A Perez; Lori J Goldstein; Stephen K L Chia; Sukhbinder Dhesy-Thind; Priya Rastogi; Emilio Alba; Suzette Delaloge; Miguel Martin; Catherine M Kelly; Manuel Ruiz-Borrego; Miguel Gil-Gil; Claudia H Arce-Salinas; Etienne G C Brain; Eun-Sook Lee; Jean-Yves Pierga; Begoña Bermejo; Manuel Ramos-Vazquez; Kyung-Hae Jung; Jean-Marc Ferrero; Anne F Schott; Steven Shak; Priyanka Sharma; Danika L Lew; Jieling Miao; Debasish Tripathy; Lajos Pusztai; Gabriel N Hortobagyi Journal: N Engl J Med Date: 2021-12-01 Impact factor: 91.245
Authors: Kathleen Iles; Mya L Roberson; Philip Spanheimer; Kristalyn Gallagher; David W Ollila; Paula D Strassle; Stephanie Downs-Canner Journal: NPJ Breast Cancer Date: 2022-03-01